Veloxis Pharmaceuticals A/S Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients
Published: Apr 28, 2014
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of a Phase II study demonstrating conversion from twice-daily tacrolimus to once-daily Envarsus® in stable liver transplant patients in Liver Transplantation.
Help employers find you! Check out all the jobs and post your resume.